Flanvotumab
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) . Flanvotumab has potent anti-tumor activity and good tolerance[1].
Product Specifications
CAS Number
[1188277-05-5]
Product Name Alternative
IMC-20D7S
UNSPSC
12352203
Target
Tyrosinase
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/flanvotumab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Flanvotumab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Khalil DN, et al. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 1;22 (21) :5204-5210.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
